About Tumor necrosis factor receptor superfamily member 6B
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B) is a protein
from Homo sapiens identified by UniProt accession
O95407, 300 residues long.
MolForge cross-references it against 0 known binders and
245 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 6B |
|---|
| UniProt accession | O95407 |
|---|
| Gene | TNFRSF6B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (245)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- ulcerative colitis · score 0.24
- Crohn's disease · score 0.22
- inflammatory bowel disease · score 0.22
- dyskeratosis congenita, autosomal recessive 5 · score 0.19
- psoriasis · score 0.18
- ankylosing spondylitis · score 0.17
- sclerosing cholangitis · score 0.17
- Eczematoid dermatitis · score 0.14
- serum gamma-glutamyl transferase measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95407-F1 | alphafold | PREDICTED | 86.65 | — |
Amino-acid sequence (300 residues)
MRALEGPGLS LLCLVLALPA LLPVPAVRGV AETPTYPWRD AETGERLVCA QCPPGTFVQR PCRRDSPTTC GPCPPRHYTQ FWNYLERCRY CNVLCGEREE EARACHATHN RACRCRTGFF AHAGFCLEHA SCPPGAGVIA PGTPSQNTQC QPCPPGTFSA SSSSSEQCQP HRNCTALGLA LNVPGSSSHD TLCTSCTGFP LSTRVPGAEE CERAVIDFVA FQDISIKRLQ RLLQALEAPE GWGPTPRAGR AALQLKLRRR LTELLGAQDG ALLVRLLQAL RVARMPGLER SVRERFLPVH
Explore Tumor necrosis factor receptor superfamily member 6B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets